皮肤癌的全基因组关联研究与多基因风险评分:临床实用吗?
该综述检索PubMed和GWAS目录,汇总了21项GWAS(黑色素瘤11项、cSCC 3项、BCC 7项)和11项PRS研究。结果显示黑色素瘤PRS约使风险增加2-3倍,预测能力仅提高2-7%;cSCC和BCC的PRS分别使风险增加约2倍和3倍,预测能力仅提高约2%。现有数据提示PRS对风险预测有小幅但可能有意义的改善。
要点
- 黑色素瘤PRS约增加2-3倍风险,预测能力仅提高2-7%。
- cSCC和BCC的PRS分别约增加2倍和3倍风险,预测能力仅提高2%。
- 三个癌种共享6个色素基因位点:ASIP/RALY、IRF4、MC1R、OCA2、SLC45A2和TYR。
核心结论
- 现有数据表明PRS可能对皮肤癌风险预测提供小幅但可能有意义的改善。
- 需要更多研究明确PRS在皮肤癌中的潜在效用。
- 临床转化需纳入已知风险因素的大样本验证研究来评估PRS作为筛查工具的价值。
研究设计与样本
- 综述检索PubMed和美国国家人类基因组研究所-欧洲生物信息研究所GWAS目录。
- 共汇总21项GWAS(黑色素瘤11项、cSCC 3项、BCC 7项)和11项PRS研究。
主要发现
- 三个癌种共享6个色素基因位点:ASIP/RALY、IRF4、MC1R、OCA2、SLC45A2和TYR。
- cSCC与BCC、BCC与黑色素瘤之间存在其他重叠位点,但cSCC与黑色素瘤之间未发现其他共享位点。
- 黑色素瘤PRS约使风险增加2-3倍,预测能力小幅提高2-7%。
- cSCC和BCC的PRS分别约使风险增加2倍和3倍,预测能力小幅提高约2%。
关键数值与推荐
- 黑色素瘤PRS:风险增加约2-3倍,预测能力提高2-7%。
- cSCC PRS:风险增加约2倍,预测能力提高约2%。
- BCC PRS:风险增加约3倍,预测能力提高约2%。
临床怎么用
- PRS目前不推荐单独用于皮肤癌风险预测或筛查。
- 临床转化需结合已知风险因素进行验证。
局限性
- PRS对风险预测的改善幅度较小(2-7%)。
- 缺乏纳入已知风险因素的大样本验证研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Genome-wide association studies (GWAS) have identified thousands of susceptibility variants, although most have been associated with small individual risk estimates that offer little predictive value. However, combining multiple variants into polygenic risk scores (PRS) may be more informative. Multiple studies have developed PRS composed of GWAS-identified variants for cutaneous cancers. This review highlights data from these studies. OBJECTIVES: To review published GWAS and PRS studies for melanoma, cutaneous squamous cell carcinoma (cSCC) and basal cell carcinoma (BCC), and discuss their potential clinical utility. METHODS: We searched PubMed and the National Human Genome Research Institute-European Bioinformatics Institute GWAS catalogue to identify relevant studies. RESULTS: Results from 21 GWAS (11 melanoma, 3 cSCC, 7 BCC) and 11 PRS studies are summarized. Six loci in pigmentation genes overlap between these three cancers (ASIP/RALY, IRF4, MC1R, OCA2, SLC45A2 and TYR). Additional loci overlap for cSCC/BCC and BCC/melanoma, but no other loci are shared between cSCC and melanoma. PRS for melanoma show roughly two-to-threefold increases in risk and modest improvements in risk prediction (2-7% increases). PRS are associated with twofold and threefold increases in risk of cSCC and BCC, respectively, with small improvements (2% increase) in predictive ability. CONCLUSIONS: Existing data indicate that PRS may offer small, but potentially meaningful, improvements to risk prediction. Additional research is needed to clarify the potential utility of PRS in cutaneous carcinomas. Clinical translation will require well-powered validation studies incorporating known risk factors to evaluate PRS as tools for screening. What's already known about this topic? Over 50 susceptibility loci for melanoma, basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC) have been identified in genome-wide association studies (GWAS). Polygenic risk scores (PRS) using variants identified from GWAS have also been developed for melanoma, BCC and cSCC, and investigated with respect to clinical risk prediction. What does this study add? This review provides an overview of GWAS findings and the potential clinical utility of PRS for melanoma, BCC and cSCC.
引用
- Roberts MR, Asgari MM, Toland AE, et al. Genome-wide association studies and polygenic risk scores for skin cancer: clinically useful yet? Br J Dermatol. 2019. PMID: 30908599. doi:10.1111/bjd.17917
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。